KEITH D. COMBRINK, Ph. D.
(817) 253-3038 • [email protected]
www.linkedin.com/in/keithcombrink/
Organic/Medicinal Chemist
Chemistry lecturer with more than 4 years’ experience at the community college and university level
teaching general chemistry and organic chemistry. Medicinal/Organic chemist with more than 7 years’
experience in industry in drug design, discovery, process chemistry, chemical information management,
organic and parallel synthesis. Invented clinical candidates for treatment of respiratory syncytial virus
infections and glaucoma. Designed novel rifamycin derivatives that retain activity against two known
rifamycin resistance mechanisms. Co-invented anti-bacterial clinical candidate CBR-2092. Numerous
publications and patents.
UNIVERSITY OF TEXAS AT ARLINGTON, Arlington Texas
Visiting Professor/Lecturer, Department of Chemistry and Biochemistry
Organic Chemistry I and II.
TARRANT COUNTY COLLEGE, Arlington, Texas
Lecturer, Department of Chemistry and Physics
General Chemistry I and II Lecture and Laboratory
2010-Present
2013-Present
ALCON/NOVARTIS, Fort Worth, TX
Principal Scientist
▪ Designed clinical candidate for novel Glaucoma target.
▪ Managed internal and external CRO resources to insure that project goals were met.
▪ Directed medicinal chemistry efforts in glaucoma and anti-infective areas.
▪ Helped prepare first non-clinical batch of clinical candidate for toxicity studies.
2007 – 2013
CUMBRE PHARMACEUTICALS, INC., Dallas, TX
Principal Scientist, Medicinal Chemistry
2002 - 2007
▪
Discovered several series of modified rifamycins as novel anti-bacterial agents for device related
infections. Co-invented clinical candidate.
▪ Designed rifamycin derivatives that are resistant to inactivation by C23 ribosylation common in
Mycobaterium avium, Mycobaterium smegmatis and Mycobacterium intracellulare.
▪ Invented a method for transient functional group protect that improved the reproducibility of a critical
step in the clinical candidate GMP synthesis.
▪
Oversaw preparation of phase I clinical supplies and provided formulation support. Co-wrote and
edited CMC section of IND.
▪ Coordinated in vivo testing of compounds at remote site and provided formulation support.
BRISTOL-MYERS SQUIBB, Wallingford, CT
1991 – 2002
Sr. Research Investigator II, Chemistry, Medicinal Chemistry
▪ Designed clinical candidate for respiratory syncytial virus (RSV)anti-viral program with novel viral
fusion inhibition mechanism. Chemistry project leader on RSV backup program.
▪ Discovered novel tryptase inhibitors and worked on HCV protease.
THE OHIO STATE UNIVERSITY, Columbus, OH
Postdoctoral Research Associate, Department of Chemistry, Leo A. Paquette, Sponsor
▪
▪
Developed new methods for the synthesis of taxanes.
Measured thermodynamic properties of novel atropisomerization using 1H NMR line shape analysis.
EDUCATION
UNIVERSITY OF KANSAS, Lawrence, KS,
▪
▪
Ph. D., Organic Chemistry
Developed new synthetic methodology for the synthesis of 2,3-dihydrobenzofurans,
bicyclo[4.2.0]octenediones and bicyclo[3.2.1]oct-3-ene-2,8-diones.
Synthesized biologically interesting pterocarpans and highly oxygenated neolignans
TEXAS CHRISTIAN UNIVERSITY, Fort Worth, TX,
B.S. Chemistry
ADDITIONAL SKILLS
Medicinal chemistry drug discovery experience with protease inhibitors, kinase inhibitors, RNA
polymerase and gyrase inhibitors, protein-protein interactions and GPCR modulation in neuroscience,
anti-viral, anti-bacterial, dermatology and cardiovascular medicinal chemistry programs. Experience with
automated liquid handlers, weighing stations, preparative HPLC systems, LC/MS, NMR, IR and OR.
Routinely utilize standard organic synthesis techniques and asymmetric synthesis techniques such as
enzymatic resolution and peptide synthesis methods. Created and maintained program databases using
ChemFinder, ISISBASE and web site to manage program data. Maintained contracts for information and
patent retrieval services. Chemdraw, ISISDRAW, Chem3D, Prous Integrity, Reaxys, MedLine, Spotfire,
MS Word, MS Excel, MS Powerpoint.
PATENTS
Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
Combrink, Keith D.; Mohapatra, Suchismita; Hellberg, Mark R.; Sharif, Najam A.; Prasanna, Ganesh;
Pang, Iok-Hou; Severns, Bryon; Chen, Hwang-Hsing; Namil, Abdelmoula ; US 8252793.
Bicyclic nitroimidazole-substituted phenyl oxazolidinones. Ding ,Charles Z.; Genliang, Lu; Combrink,
Keith D.; Chen, Dianjun D.; Song, Minsoo; Wang, Jinacheng; Ma, Zhenkun; Palmer, Brian Desmond;
Blaser, Adrian; Thompson, Andrew M.; Kmentova, Iveta;, Sutherland, Hamish Scott; Denny, William
Alexander; US 7,666,864.
Preparation of nitroheteroaryl-containing rifamycin derivatives as antibacterial agents. Ding, Charles Z.;
Kim, In Ho; Wang, Jiancheng; Ma, Zhenkun; Jin, Yafei; Combrink, Keith D.; Lu, Genliang; Lynch, A.
Simon. WO 2008008480 A2
Quinolone carboxylic acid substituted rifamycin derivatives. Ding, Charles, Z, Jin, Yafei, Combrink,
Keith, Kim, In Ho; US7884099.
Preparation of C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes.
Combrink, Keith; Harran, Susan; Denton, Daniel; Ma, Zhenkun., US7250413, July 31, 2007.
Rifamycin derivatives effective against drug-resistant microbes. Ma; Zhenkun., Jin; Yafei, Li; Jing, Ding;
Charles. Z., Minor; Keith. P., Longgood; Jamie. C., Kim; In Ho, Harran; Susan., Combrink; K., Morris;
T. W.; Cumbre Pharmaceuticals Inc. (Dallas, TX), US7247634, June 12, 2007.
Rifamycin derivatives, Ma; Zhenkun, Li; Jing, Harran; Susan, He; Yong, Minor; Keith P., Kim; In Ho,
Ding; Charles Z., Longgood; Jamie C., Jin; Yafei, Combrink; Keith. D.; Cumbre Pharmaceuticals Inc.
(Dallas, TX) US7229996, June 12, 2007.
(R/S) rifamycin derivatives, their preparations and pharmaceutical compositions Ding; Charles Z., Ma;
Zhenkun, Li; Jing, Harran; Susan, He; Yong, Minor; Keith P., Kim; In Ho, Longgood; Jamie C., Jin;
Yafei, Combrink; Keith D., US7226931, June 5, 2007.
Substituted 2-methyl-benzimidazole respiratory syncytial virus Antiviral Agents; Yu, Kuo-Long, Wang,
Xiangdong; Sun, Xiaxiong; Cianci, Christopher; Thuring, Jan Wilhelm; Combrink, Keith , Meanwell,
Nicholas, Zhang, Zi; Civiello, Rita; WO2003053344A2, PCT, July 3, 2003, US6919331, July 19, 2005.
Heterocyclic substituted 2-methyl-benzimidazole antiviral agents; Yu, Kuo-Long, Wang, Xiangdong; Sun,
Xiaxiong; Cianci, Christopher; Thuring, Jan Wilhelm; Combrink, Keith , Meanwell, Nicholas, Zhang, Zi;
Civiello, Rita; WO2002062290, PCT, July 3, 2003, US6844342, January 18, 2005.
Imidazopyridine and Imidazopyrimidine Antiviral Agents; Kuo-Long Yu, Rita L. Civiello, Keith D.
Combrink, Hatice Belgin Gulgeze, Ny Sin, Xiangdong Wang, Nicholas A. Meanwell, WO0195910
(2001); US6489338, Dec. 3, 2002.
Benzimidazolone Antiviral Agents useful for treating RSV infection; Kuo-Long Yu, Rita L. Civiello,
Keith D. Combrink, Hatice Belgin Gulgeze, Xiangdong Wang, Nicholas A. Meanwell, Yi Zhang, Bradley
C. Pearce, WO0226228 (2002), US6506738.
Heterocyclic substituted 2-methyl-benzimidazole antiviral agents: Kuo-Long Yu, Rita L. Civiello, Keith
D. Combrink, Hatice Belgin Gulgeze, Ny Sin, Xiangdong Wang, Nicholas A. Meanwell, Brian L.
Venables, Bradley C Pearce, Zhiwei Yin, Jan Willem Thuring, WO200262290. US6774134, August 10,
2004.
Antimigraine 4-Pyrimidinyl and Pyridinyl Derivatives Indol-3yl Alkylpiperazines, David W. Smith;
Frank D. Yocca; Joseph P. Yevich; Ronald J. Mattson; Andrew Williams; Edward H. Ruediger; Keith
Dean Combrink; Bradley Clyde Pearce, US Patent 5,434,154; EP0548813.
PUBLICATIONS
Discovery and Structure-Based Optimization of Adenain Inhibitors, Mac Sweeney, A,; Grosche, P.; Ellis,
D.; Combrink, K.; Erbel, P.; Hughes, N.; Sirockin, F.; Melkko, S.; Bernardi, A.; Ramage, P.; Harousse,
N.; Altmann, E. ACS Medicinal Chemistry Letters, 2014, 5 (8), 937–941.
In vivo optimization of 2,3-diaminopyrazine Rho Kinase inhibitors for the treatment of Glaucoma
Bioorganic & Medicinal Chemistry Letters; Hwang-Hsing Chen,; Abdelmoulah N Namil; Bryon Severns;
Jennifer Ward,; Curtis Kelly, PhD; Colene Drace; Marsha A McLaughlin; Shenouda Yacoub; Byron Li;
Raj Patil; Naj Sharif; Mark R Hellberg; Andrew Rusinko; Bioorganic & Medicinal Chemistry Letters,
2014, 24, 1875-1879.
Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic
Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection; Paul M. Scola,,
Alan Xiangdong Wang, Andrew C. Good, Li-Qiang Sun, Keith D. Combrink, Jeffrey A. Campbell, Jie
Chen, Yong Tu, Ny Sin, Brian L. Venables, Sing-Yuen Sit, Yan Chen, Anthony Cocuzza, Donna M.
Bilder, Stanley D’Andrea, Barbara Zheng, Piyasena Hewawasam, Min Ding, Jan Thuring, Jianqing Li,
Dennis Hernandez, Fei Yu, Paul Falk, Guangzhi Zhai, Amy K. Sheaffer, Chaoqun Chen, Min S. Lee,
Diana Barry, Jay O. Knipe,Wenying Li, Yong-Hae Han, Susan Jenkins, Christoph Gesenberg, Qi Gao,
Michael W. Sinz, Kenneth S. Santone, Tatyana Zvyaga, Ramkumar Rajamani, Herbert E. Klei, Richard J.
Colonno, Dennis M. Grasela, Eric Hughes, Caly Chien, Stephen Adams, Paul C. Levesque, Danshi Li,
Jialong Zhu, Nicholas A. Meanwell, and Fiona McPhee, Journal of Medicinal Chemistry 2014,
57(5):1708-29.
Rho-Rho kinase p
athway in the actomyosin contraction and cell-matrix adhesion in immortalized human trabecular
meshwork cells; Ramachandran, C.; Patil, R. V.; Combrink, K.; Sharif, N. A.; Srinivas, S. P. ; Molecular
Vision (2011), 17, 1877-1890.
Respiratory syncytial virus fusion inhibitors. Part 7: Structure–activity relationships associated with a
series of isatin oximes that demonstrate antiviral activity in vivo, Ny Sin, Brian L. Venables, Keith D.
Combrink, H. Belgin Gulgeze, Kuo-Long Yu, Rita L. Civiello, Jan Thuring, X. Alan Wang, Zheng Yang,
Lisa Zadjura, Anthony Marino, Kathleen F. Kadow, Christopher W. Cianci, Junius Clarke, Eugene V.
Genovesi, Ivette Medina, Lucinda Lamb, Mark Krystal, Nicholas A. Meanwell; Bioorganic & Medicinal
Chemistry Letters, 19 (2009) 4857-4862.
Respiratory syncytial virus fusion inhibitors. Part 6: An examination of the effect of structural variation of
the benzimidazol-2-one heterocycle moiety, Keith D. Combrink, H. Belgin Gulgeze, Jan W. Thuring,
Kuo-Long Yu, Rita L. Civiello, Yi Zhang, Bradley C. Pearce, Zhiwei Yin, David R. Langley, Kathleen F.
Kadow, Christopher W. Cianci, Zhufang Li, Junius Clarke, Eugene V. Genovesi, Ivette Medina, Lucinda
Lamb, Zheng Yang, Lisa Zadjura, Mark Krystal and Nicholas A. Meanwell; Bioorganic & Medicinal
Chemistry Letters, 2007, 17 (2007) 4784–4790.
Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns
towards derivatives with improved activity, Xiangdong Alan Wang, Christopher W. Cianci, Kuo-Long
Yu, Keith D. Combrink, Jan W. Thuring, Yi Zhange, Rita Civiello, Kathleen F. Kadow, Julai Roach,
Zhufang Li, David R. Langley, Mark Krystal, Nicholas A. Meanwell, Bioorganic & Medicinal Chemistry
Letters, 2007, 17 4592–4598.
Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins In Ho Kim, Keith
D. Combrink, Zhenkun Ma, Katrina Chapo, Dalai Yan, Paul Renick, Timothy W. Morris, Mark Pulse,
Jerry W. Simecka and Charles Z. Ding; Bioorganic & Medicinal Chemistry Letters, 2007, 17, 1181-1184.
Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability; Kuo-Long Yu,
Ny Sin, Rita L. Civiello, X. Alan Wang, Keith D. Combrink, H. Belgin Gulgeze, Brian L. Venables, J. J.
Kim Wright, Richard A. Dalterio, Lisa Zadjura, Anthony Marino, Sandra Dando, Celia D’Arienzo,
Kathleen F. Kadow, Christopher W. Cianci, Zhufang Li, Junius Clarke, Eugene V. Genovesi, Ivette
Medina, Lucinda Lamb, Richard J. Colonno, Zheng Yang, Mark Krystal Nicholas A. Meanwell,
Bioorganic & Medicinal Chemistry Letters, 2007, 17, 895–901.
New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases; Keith
D. Combrink;. Daniel A. Denton, Susan Harran, Zhenkun Ma, Katrina Chapo, Dalai Yan, Eric
Bonventre, Eric D. Roche, Timothy B. Doyle. Gregory T. Robertson and Anthony S. Lynch; Bioorganic
& Medicinal Chemistry Letters, 2007, 17(2), 522-526.
Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with
antiviral activity in vivo Yu, Kuo-Long; Wang, Xiangdong Alan; Civiello, Rita L.; Trehan, Ashok K.;
Pearce, Bradley C.; Yin, Zhiwei; Combrink, Keith D.; Gulgeze, H. Belgin; Zhang, Yi; Kadow, Kathleen
F.; Cianci, Christopher W.; Clarke, Junius; Genovesi, Eugene V.; Medina, Ivette; Lamb, Lucinda; Wyde,
Philip R.; Krystal, Mark; Meanwell, Nicholas A. Bioorganic & Medicinal Chemistry Letters, 2006,
16(5), 1115-1122.
Orally Active Fusion Inhibitor of Respiratory Syncytial Virus; Cianci, Christopher; Yu, Kuo-Long;
Combrink, Keith; Sin, Ny; Pearce, Bradley; Wang, Alan ; Civiello, Rita; Voss, Stacey; Luo, Guangxiang;
Kadow, Kathy; Genovesi, Eugene V.; Venables, Brian; Gulgeze, Hatice; Trehan, Ashok; James, Jennifer;
Lamb, Lucinda; Medina, Ivette; Roach, Julia; Yang, Zheng; Zadjura, Lisa; Colonno, Richard; Clark,
Junius; Meanwell, Nicholas; Krystal, Mark; Antimicrobial Agents and Chemotherapy, 2004, 48(2), 413–
422.
Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives; Yu, Kuo-Long, Zhang, Yi;
Civiello, Rita L Trehan, Ashok K., Pearce, Bradley C., Zhiwei Yin, Zhiwei;, Keith D. Combrink, Keith
D.; Gulgeze, H. Belgin; Wang, Xiangdong Alan; Kadow, Kathleen F.; Cianci, Christopher W.; Krystal,
Mark; Meanwell, Nicholas A.; Bioorganic & Medicinal Chemistry Letters, 2004, 14, 1133–1137.
Salicylamide Inhibitors of Influenza Virus Fusion; Keith D. Combrink, H. Belgin Gulgeze, Kuo-Long Yu,
Bradley C. Pearce, Ashok K. Trehan, Jianmei Wei, Milind Deshpande, Mark Krystal, Albert Torri,
Guangxiang Luo, Christopher Cianci, Stephanie Danetz, Laurence Tiley and Nicholas A. Meanwell,
Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1649-1652.
From D-camphor to the taxanes. highly concise rearrangement-based approaches to taxusin and taxol ;
Paquette, Leo A.; Zhao, Mangzhu; Montgomery, Francis; Zeng, Qingbei; Wang, Ting Zhong; Elmore,
Steven; Combrink, Keith; Wang, Hui-Ling; Bailey, Simon; Su, Zhuang ; Edited by Scolastico, Carlo;
Nicotra, Francecso; Current Trends in Organic Synthesis, [Proceedings of the International Conference
on Organic Synthesis], 12th, Venezia, June 28-July 2, 1998 (1999), 25-34.
1,2-Benisothiazol-3-one 1,1-Dioxide Inhibitors of Human Mast Cell Tryptase, Combrink, Keith; Gulgeze,
H. Belgin, Meanwell, Nicholas A.; Pearce, Bradley C.; Zulan, Pi; Bisacchi, Gregory S.; Roberts, Daniel G.
M.; Stanley, Paul; Seiler, Steven M., The Journal of Medicinal Chemistry, 1998, 41, 4854-4860.
From D-camphor to the taxanes. Highly concise rearrangement-based approaches to taxusin and taxol., L.
A. Paquette, M. Z. Zhao, F. Montgomery, Q. B. Zeng, T. Z. Wang, S. Elmore, K. Combrink, H. L.
Wang, S. Bailey, Z. A. Su. Pure and Applied Chemistry 1998, 70(8), 1449-1457.
Synthesis of H-3 Labeled 5-Fluoro-3-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]propyl-1H-indole, A
Serotonergic Agent with Potential Antidepressant Activity, Douglas D. Dischino, Keith D. Combrink,
Lidia Doweyko, Hiromi Morimoto, Bradley C. Pearce, Philip G. Williams, Joseph P. Yevich, Journal of
Labelled Compounds and Radiopharmaceuticals, 1995, 36(8), 789-794.
Regioselective Lewis Acid-Directed Reactions of 2-Alkoxy-5-alkyl-1,4- benzoquinones with Styrenes:
Synthesis of Burchellin and Guianin Neolignans Thomas A. Engler, Dong (Donna) Wei, Michael A.
Letavic, Keith D. Combrink, Jayachandra P. Reddy, The Journal of Organic Chemistry 1994, 59, 658899.
Stereospecific Lewis Acid Promoted Reactions of Styrenyl Systems with 2-Alkoxy-(6-alkyl)-1,4benzoquinones: Scope, Limitations and Synthetic Applications, Thomas A. Engler, Keith D. Combrink,
Michael A. Letavic, Kenneth O. Lynch, Jr, and James E. Ray, The Journal of Organic Chemistry 1994,
59, 6567-87.
An enantioselective approach to the taxanes:
direct access to functionalized cis3,8
tricyclo[9.3.1.0 ]pentadecanes via alpha-hydroxy ketone and Wagner-Meerwein rearrangements, Leo A.
Paquette; Steve W. Elmore; Keith D. Combrink; Eugene R. Hickey; Robin D. Rogers, Helv. Chim. Acta,
1992,75, 1755-71
Setting the bridgehead oxidation level in transtricyclo[9.3.1.03,8]pentadecanes as a prelude to the dual
synthesis of taxol and taxusin, Leo A. Paquette, Keith D. Combrink, Steven W. Elmore, Manzhu Zhao,
Helv. Chim. Acta, 1992, 75, 1772-91.
A Convenient Means for Controlling the Oxidation Level of Bridgehead Carbon C-1 in Functionalized
Tricyclo[9.3.1.03,8]pentadecanes, Steven W. Elmore, Keith D. Combrink, Leo A. Paquette, Tetrahedron
Letters, 1991, 32, 6679.
Impact of Substituent Modifications on the Atropselectivity Characteristics of an Anionic Oxy-Cope
Ring Expansion, Leo A. Paquette, Keith D. Combrink, S. W. Elmore and Robin D. Rogers, Journal of the
American Chemical Society. 1991, 113, 1335.
Selective Control of the Various Cycloaddition Products from Reactions of Styrenes and 1,4Benzoquinones: Optimization of the Formal 5+2 Cycloadducts, Thomas A. Engler, Michael A. Letavic,
Keith D. Combrink, Fusao Takusagawa, The Journal of Organic Chemistry, 1990, 55, 5810.
Formal 2+2 and 3+2 Cycloaddition Reactions of 2H -Chromenes with 2-Alkoxy 1,4- benzoquinones:
Regioselective Synthesis of Substituted Pterocarpans, Thomas A. Engler, Jayachandra P. Reddy, Keith D.
Combrink, David Vander Velde, The Journal of Organic Chemistry, 1990, 55, 1248.
A New Regioselective Synthesis of Pterocarpans, Thomas A. Engler, Jayachandra P. Reddy and Keith D.
Combrink, Journal of the Chemical Society, Chemical Communications, 1989, 454.
Isolation of Bicyclo[3.2.1]oct-3-ene-2,8-dione Products (Formal 5+2 Cycloadducts) from Reaction of
Styrenes with 2-Alkoxy-1,4-benzoquinones Thomas A. Engler, Keith D. Combrink and Fusao
Takusagawa, Journal of the Chemical Society, Chemical Communications, 1989, 1573.
An Efficient Method for the Synthesis of 1-Arylalkynes, Thomas A. Engler, Keith D. Combrink and
James E. Ray, Synthetic Communications, 1989, 19, 1735.
3+2 and Stereospecific 2+2 Cycloaddition Reactions of Alkenes and Quinones, Thomas A. Engler, Keith
D. Combrink and James E. Ray Journal of the American Chemical Society , 1988, 110, 7931.
REVIEWS
New rifamycins for the treatment of bacterial infections, Keith D. Combrink, A. Simon Lynch, Expert
Opinion on Therapeutic Patents, May, 2007, 17(5):475-485.
Therapeutic Opportunities for the Treatment of Device-Associated Infections. Zhenkun Ma; Tim Morris;
Keith Combrink; Annual Reviews in Medicinal Chemistry, Annual Reports in Medicinal Chemistry, 2004,
39 197-210.
Non-HIV Antivirals – A review of recent patent literature, Keith Combrink, IDrugs, 2002, 5(8), 815-827.
Asymmetric Induction in the Ene Reactions of N-Sulfinylcarbamates, Keith D. Combrink, Leo A.
Paquette, Chemtracts-Organic Chemistry 1991, 4, 164.
ACS NATIONAL MEETING ABSTRACTS
Discovery and SAR of tripeptide acylsulfonamides as potent inhibitors of HCV NS3 protease; Scola, Paul
M.; Good, Andrew C.; Campbell, Jeffrey A.; Klei, Herbert E.; Wang, Alan X.; Chen, Jie; Sit, Sing-Yuen;
Ripka, Amy; Chen, Yan; Thurling, Yan; Combrink, Keith et al; Abstracts of Papers, 238th ACS National
Meeting, Washington, DC, United States, August 16-20, 2009 (2009), MEDI-229.
HCV NS3 Protease Inhibitors: Modifications at P3; Venables, Brian L.; Sin, Ny; Campbell, Jeffrey A.;
Tu, Yong; Hewawasam, Piyasena; Sit, Sing-Yuen; Chen, Yan; Combrink, Keith; Ripka, Amy; Sheaffer,
Amy K.; Combrink, Keith et al; Abstracts, 36th Northeast Regional Meeting of the American Chemical
Society, Hartford, CT, United States, October 7-10 (2009), NERM-181.
Novel Acyclic Monosubstituted Isoquinolinyl Tripeptides as HCV NS3 Protease Inhibitors; Chen, Jie;
Sun, Li-Qiang; Wang, Alan; Sit, Sing-Yuen; Chen, Yan; Hewawasam, Piyasena; Tu, Yong; Ding, Min;
D'Andrea, Stanley; Zheng, Zhizhen; Combrink, Keith et al; Abstracts, 36th Northeast Regional Meeting
of the American Chemical Society, Hartford, CT, United States, October 7-10 (2009), NERM-179.
SAR elucidation of the P3 subregion of HCV NS3 protease inhibitors; Sin, Ny; Venables, Brian L.; Tu,
Yong; Hewawasam, Piyasena; Sit, Sing-Yuen; Chen, Yan; Campbell, Jeffrey A.; Combrink, Keith; Ripka,
Amy; Sheaffer, Amy; et al; Abstracts of Papers, 238th ACS National Meeting, Washington, DC, United
States, August 16-20, 2009 (2009), MEDI-112.
Synthesis and SAR of a series of potent and novel acyclic monosubstituted isoquinolinyl tripeptides as
HCV NS3 protease inhibitors; Sun, Li-Qiang; Wang, Alan X.; Chen, Jie; Sit, Sing-Yuen; Chen, Yan;
Hewawasam, Piyasena; Tu, Yong; Ding, Min; D'Andrea, Stanley V.; Zheng, Zhizhen B.; Combrink,
Keith et al; Abstracts of Papers, 238th ACS National Meeting, Washington, DC, United States, August
16-20, 2009 (2009), MEDI-110.
Synthesis and SAR of Novel HCV NS3 Protease Inhibitors ; Chen, Yan; Sit, S. Y.; Wang, Alan X.; Chen,
Jie; Sun, Li-Qiang; Hewawasam, Piyasena; Tu, Yong; Ding, Min; D'Andrea, Stanley V.; Zheng, Zhizhen;
Combrink, Keith et al ; From Abstracts, 36th Northeast Regional Meeting of the American Chemical
Society, Hartford, CT, United States, October 7-10 (2009), NERM-178.
The Code of Life ; Combrink, Keith; Samanta, Himadri; Abstracts, 59th Southwest Regional Meeting of
the American Chemical Society, Oklahoma City, OK, United States, October 25-28 (2003), 166.